Uncategorized
September 10, 2021 / January 12, 2026 by necteromedical
Proceeds from new investors will fund in vivo and clinical development of innovative platform for aneurysmal disease, including Abdominal Aortic Aneurysms (AAA) TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Therapeutics Inc. today announced the closing of its $19.5 million Series C financing round, led by new investor Boston Scientific Corporation, a leading global medical device manufacturer. Proceeds will support the company’s in […]
Read more »